Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/372
Title: The effect of exit-site antibacterial honey versus nasal mupirocin prophylaxis on the microbiology and outcomes of peritoneal dialysis-associated peritonitis and exit-site infections: A sub-study of the Honeypot trial
Authors: McTaggart, S.
Geoffrey Playford, E. 
Isbel, N. M.
Snelling, P. 
Badve, S. V.
Scaria, A.
Beller, E.
Cass, A.
Zhang, L.
De Zoysa, J.
Vergara, L. A.
Morrish, A. T.
Clark, C.
Pascoe, E. M.
Johnson, D. W.
Hawley, C. M.
Issue Date: 2015
Source: 35, (7), 2015, p. 712-721
Pages: 712-721
Journal: Peritoneal Dialysis International
Abstract: Background: The HONEYPOT study recently reported that daily exit-site application of antibacterial honey was not superior to nasal mupirocin prophylaxis for preventing overall peritoneal dialysis (PD)-related infection. This paper reports a secondary outcome analysis of the HONEYPOT study with respect to exit-site infection (ESI) and peritonitis microbiology, infectious hospitalization and techniquefailure. Methods: A total of 371 PD patients were randomized to daily exit-site application of antibacterial honey plus usual exit-site care (N = 186) or intranasal mupirocin prophylaxis (in nasal Staphylococcus aureus carriers only) plus usual exit-site care (control, N = 185). Groups were compared on rates of organism-specific ESI and peritonitis, peritonitis-and infection-associated hospitalization, and technique failure (PD withdrawal). Results: The mean peritonitis rates in the honey and control groups were 0.41 (95% confidence interval [CI] 0.32-0.50) and 0.41 (95% CI 0.33-0.49) episodes per patient-year, respectively (incidence rate ratio [IRR] 1.01, 95% CI 0.75-1.35). When specific causative organisms were examined, no differences were observed between the groups for gram-positive (IRR 0.99, 95% CI 0.66-1.49), gram-negative (IRR 0.71, 95% CI 0.39-1.29), culture-negative (IRR 2.01, 95% CI 0.91-4.42), or polymicrobial peritonitis (IRR 1.08, 95% CI 0.36-3.20). Exit-site infection rates were 0.37 (95% CI 0.28-0.45) and 0.33 (95% CI 0.26-0.40) episodes per patient-year for the honey and control groups, respectively (IRR 1.12, 95% CI 0.81-1.53). No significant differences were observed between the groups for gram-positive (IRR 1.10, 95% CI 0.70-1.72), gram-negative (IRR: 0.85, 95% CI 0.46-1.58), culture-negative (IRR 1.88, 95% CI 0.67-5.29), or polymicrobial ESI (IRR 1.00, 95% CI 0.40-2.54). Times to first peritonitis-associated and first infection-associated hospitalization were similar in the honey and control groups. The rates of technique failure (PD withdrawal) due to PD-related infection were not significantly different between the groups. Conclusion: Compared with standard nasal mupirocin prophylaxis, daily topical exit-site application of antibacterial honey resulted in comparable rates of organism-specific peritonitis and ESI, infection-associated hospitalization, and infection-associated technique failure in PD patients.
Resources: http://linksource.ebsco.com/ls.b6e6cc08-c492-42af-aec4-c6084e18e68c.true/linking.aspx?sid=EMBASE&issn=17184304&id=doi:10.3747%2Fpdi.2014.00206&atitle=The+effect+of+exit-site+antibacterial+honey+versus+nasal+mupirocin+prophylaxis+on+the+microbiology+and+outcomes+of+peritoneal+dialysis-associated+peritonitis+and+exit-site+infections%3A+A+sub-study+of+the+Honeypot+trial&stitle=Peritoneal+Dial.+Int.&title=Peritoneal+Dialysis+International&volume=35&issue=7&spage=712&epage=721&aulast=&aufirst=&auinit=&aufull=+&coden=PDIIE&isbn=&pages=712-721&date=2015&auinit1=&auinitm=
http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L607393225http://dx.doi.org/10.3747/pdi.2014.00206
Keywords: clinical trialconfidence interval;control group;controlled clinical trial;controlled study;disease carrier;honey;hospitalization;human;incidence;infection;infection rate;major clinical study;microbiology;peritoneal dialysis;peritonitis;prophylaxis;randomized controlled trial;Staphylococcus aureus;topical drug administration;antiinfective agent;pseudomonic acid
Type: Article
Appears in Sites:Sunshine Coast HHS Publications

Show full item record

Page view(s)

162
checked on Mar 27, 2025

Google ScholarTM

Check


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.